Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Short Interest Down 26.7% in May

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Get Free Report) was the target of a large drop in short interest in the month of May. As of May 15th, there was short interest totalling 43,900 shares, a drop of 26.7% from the April 30th total of 59,900 shares. Based on an average daily trading volume, of 212,000 shares, the days-to-cover ratio is currently 0.2 days. Currently, 0.0% of the company's stock are sold short.

Xtant Medical Stock Up 3.7%

Shares of Xtant Medical stock traded up $0.03 on Thursday, hitting $0.71. 57,323 shares of the company's stock traded hands, compared to its average volume of 121,344. The stock has a market cap of $98.32 million, a P/E ratio of -5.44 and a beta of 0.35. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The firm's 50-day moving average is $0.54 and its 200 day moving average is $0.52. Xtant Medical has a 52-week low of $0.33 and a 52-week high of $0.83.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Xtant Medical stock. Renaissance Technologies LLC grew its holdings in shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT - Free Report) by 15.0% in the fourth quarter, according to its most recent filing with the SEC. The firm owned 798,033 shares of the medical device company's stock after acquiring an additional 103,825 shares during the quarter. Renaissance Technologies LLC owned about 0.57% of Xtant Medical worth $354,000 as of its most recent SEC filing. 69.33% of the stock is owned by hedge funds and other institutional investors.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.